4/20
07:06 am
phvs
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference [Yahoo! Finance]
Neutral
Report
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference [Yahoo! Finance]
4/20
06:50 am
phvs
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Neutral
Report
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
4/15
05:00 pm
phvs
Pharvaris (PHVS) had its "buy" rating reaffirmed by Citigroup Inc..
Low
Report
Pharvaris (PHVS) had its "buy" rating reaffirmed by Citigroup Inc..
4/13
01:00 am
phvs
Medium
Report
4/10
06:09 am
phvs
Pharvaris (PHVS) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Pharvaris (PHVS) was upgraded by Wolfe Research to "strong-buy".
4/9
09:00 am
phvs
Pharvaris (PHVS) is now covered by Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.
Low
Report
Pharvaris (PHVS) is now covered by Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.
4/7
08:42 am
phvs
Pharvaris (PHVS) had its price target raised by Wedbush from $41.00 to $42.00. They now have an "outperform" rating on the stock.
Low
Report
Pharvaris (PHVS) had its price target raised by Wedbush from $41.00 to $42.00. They now have an "outperform" rating on the stock.
4/6
08:47 pm
phvs
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris' (PHVS) Investment Narrative? [Yahoo! Finance]
Low
Report
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris' (PHVS) Investment Narrative? [Yahoo! Finance]
4/6
11:43 am
phvs
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says [Yahoo! Finance]
Low
Report
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says [Yahoo! Finance]
4/6
09:23 am
phvs
Pharvaris (PHVS) had its price target lowered by Royal Bank Of Canada from $52.00 to $51.00. They now have an "outperform" rating on the stock.
Low
Report
Pharvaris (PHVS) had its price target lowered by Royal Bank Of Canada from $52.00 to $51.00. They now have an "outperform" rating on the stock.
4/5
01:06 am
phvs
Low
Report
4/2
08:09 pm
phvs
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
4/2
07:05 am
phvs
Pharvaris reports Q4 results [Seeking Alpha]
Medium
Report
Pharvaris reports Q4 results [Seeking Alpha]
4/2
06:50 am
phvs
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/28
01:05 am
phvs
Low
Report
3/20
07:10 am
phvs
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
Low
Report
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
3/12
11:12 am
phvs
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
3/11
06:50 am
phvs
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Medium
Report
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
3/9
09:56 am
phvs
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
Neutral
Report
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
3/3
12:16 pm
phvs
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
3/2
07:09 am
phvs
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 [Yahoo! Finance]
Low
Report
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 [Yahoo! Finance]
3/2
06:50 am
phvs
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Low
Report
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
2/28
01:30 am
phvs
Low
Report
2/10
07:02 am
phvs
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting [Yahoo! Finance]
Low
Report
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting [Yahoo! Finance]
2/10
06:50 am
phvs
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Low
Report
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting